You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
昊海生物科技(06826.HK)年度归母净利上升53.1%至3.52亿元 末期息0.7元
格隆汇 03-29 07:26

格隆汇3月29日丨昊海生物科技(06826.HK)发布2021年全年业绩公吿,报吿期内,集团实现营业收入约为人民币17.501亿元,同比增幅约为32.14%。报吿期内,集团持续加大研究与开发投入,着重扩充眼科和医美创新产品线,报吿期内发生的研发费用约为人民币1.676亿元,同比增幅为32.51%。报吿期内,研发费用占集团营业收入比重达到9.58%。报吿期内,集团归属于上市公司股东的净利润及归属于上市公司股东的扣除非经常性损益的净利润分约为人民币3.522亿元和人民币3.28亿元,较上年度分别上升53.10%和58.88%。基本每股盈利人民币2元,董事会建议派发年度末期股息为每股人民币0.7元(含税)。

报吿期内,随着国内疫情得到有效控制,疫情对于集团经营活动的影响逐渐减弱,集团各项业务均全面恢复,各产品线的销售收入均较2020年实现显著增长。报吿期内,集团整体毛利率为71.98%,较2020年的74.78%有所下降,主要原因为,一方面,集团根据相关会计准则规定,对于非同一控制下企业合并中所取得的欧华美科及其附属公司的账面存货,在股权收购日以可销售价格作为其公允价值重新计量,并在相关存货实现销售时以相应公允价值结转当期营业成本,使得集团合并报表中对于该等存货的销售毛利率为零,将报吿期内的整体毛利率拉低了约1.26%;另一方面,集团眼科人工晶状体产品部分型号在实施带量采购的区域销售价格有所下降,此外,集团稳步下调了玻尿酸产品的销售价格,以突出其“国民玻尿酸”的产品定位。集团的人工晶状体及玻尿酸产品线均拥有丰富的产品布局,部分中低端产品价格下调对毛利率产生了阶段性影响,集团将通过努力提升中高端及高端产品的销售占比,以稳定整体毛利率。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account